Table I.
Clinical data for primary hematological malignancy of uterine cervix.
| Case number | Age, years | LDH, U/l | Stage | Mass of uterine cervix, cm | Biopsy | Pathological type | Treatment | Treatment outcome | OS, months |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 65 | 221 | IIEA | 6×2 | Yes | DLBCL | Surgery, CT | Alive with CR | 35 |
| 2 | 43 | 210 | IEA | 4.5 | No | MALToma | Surgery, CT | Alive with CR | 82a |
| 3 | 36 | 169 | IEA | 4×3 | Yes | DLBCL | CT | Alive with CR | 73 |
| 4 | 46 | 133 | IIEA | 6×5 | Yes | MS | Surgery, CT | Succumbed to progressive disease | 21 |
| 5 | 39 | 1,014 | IVEA | 6.9×5.6 | Yes | MS | Surgery, CT | Succumbed to leukemia | 26 |
a
Lost to follow-up. MALToma, mucosa associated lymphoid tissue lymphoma; DLBCL, diffuse large B cell lymphoma; MS, myeloid sarcoma; CT, chemotherapy; CR, complete remission; LDH, lactate dehydrogenase; OS, overall survival.